Literature DB >> 18676326

Updates in non-small cell lung cancer.

Suzanne Walker1.   

Abstract

Lung cancer is the leading cause of cancer death in both men and women. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing more than 80% of lung cancer diagnoses. Five-year survival remains at 15%, but new strategies for prevention, early detection, and treatment may improve survival rates. This article provides an overview of updates in NSCLC, with an emphasis on advances in treatment strategies. Newer targeted therapies, as well as advances in genetic blueprinting, will be discussed. Nurses play a pivotal role in the assessment and management of patients with NSCLC and, therefore, must remain abreast of the most current prevention, screening, and treatment options.

Entities:  

Mesh:

Year:  2008        PMID: 18676326     DOI: 10.1188/08.CJON.587-596

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  26 in total

1.  Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.

Authors:  Yafei Li; Zhifu Sun; Julie M Cunningham; Marie C Aubry; Jason A Wampfler; Gary A Croghan; Cassandra Johnson; Danli Wu; Jeremiah A Aakre; Julian Molina; Liewei Wang; V Shane Pankratz; Ping Yang
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a.

Authors:  Jacqueline C Shultz; Rachel W Goehe; D Shanaka Wijesinghe; Charuta Murudkar; Amy J Hawkins; Jerry W Shay; John D Minna; Charles E Chalfant
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

3.  Longer overall survival in a patient with advanced non-small cell lung cancer treated with Chinese medicine and chemotherapy.

Authors:  Yan-Zhi Chen; Zhan-Dong Li; Ning Zhou; Hong Sun; Ping-Ping Li
Journal:  Chin J Integr Med       Date:  2012-08-02       Impact factor: 1.978

4.  A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced non-small cell lung cancer.

Authors:  Wei Hu; Zhiping Zhang
Journal:  Med Oncol       Date:  2015-05-06       Impact factor: 3.064

5.  A multi-center phase II study of nintedanib as second-line therapy for patients with advanced non-small-cell lung cancer in China.

Authors:  Wenxin Dai; Bailing Luo; Zhiyong Wu; Juan Chen; Guangqiu Feng; Ping Guan
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

6.  Reduced expression levels of PTEN are associated with decreased sensitivity of HCC827 cells to icotinib.

Authors:  Yang Zhai; Yanjun Zhang; Kejun Nan; Xuan Liang
Journal:  Oncol Lett       Date:  2017-03-08       Impact factor: 2.967

7.  Synergistic inhibitory effect of berberine and icotinib on non-small cell lung cancer cells via inducing autophagic cell death and apoptosis.

Authors:  Ping Chen; Chun-Hua Dai; Zhi-Hao Shi; Yi Wang; Jian-Nong Wu; Kang Chen; Jin-Yu Su; Jian Li
Journal:  Apoptosis       Date:  2021-11-07       Impact factor: 4.677

8.  Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesis.

Authors:  Jian Liu; Sung-Nam Cho; San-Pin Wu; Nili Jin; Seyed Javad Moghaddam; Jennifer L Gilbert; Ignacio Wistuba; Francesco J DeMayo
Journal:  Lung Cancer       Date:  2017-08-05       Impact factor: 5.705

9.  PPARα activation can help prevent and treat non-small cell lung cancer.

Authors:  Nataliya Skrypnyk; Xiwu Chen; Wen Hu; Yan Su; Stacey Mont; Shilin Yang; Mahesha Gangadhariah; Shouzuo Wei; John R Falck; Jawahar Lal Jat; Roy Zent; Jorge H Capdevila; Ambra Pozzi
Journal:  Cancer Res       Date:  2013-12-03       Impact factor: 12.701

10.  Prophylactic cranial irradiation in non-small cell lung cancer patients: who might be the candidates?

Authors:  Charalampos Dimitropoulos; Georgios Hillas; Sofia Nikolakopoulou; Ioanna Kostara; Konstantinos Sagris; Fotis Vlastos; Manos Alchanatis
Journal:  Cancer Manag Res       Date:  2011-08-17       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.